NCT02425722CompletedPhase 2
Phase II Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study in Patients With Chronic Constipation (Not Including Constipation Due to Organic Diseases)
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Astellas Pharma Inc
- Enrollment
- 383
- Locations
- 50
- Primary Endpoint
- Change in weekly average of SBM frequency
Study Overview
Brief Summary
The objective of this study is to investigate dose-responses of efficacy and safety of ASP0456 in patients with chronic constipation (diagnosed by Rome III criteria of functional constipation (FC), not including constipation due to organic diseases) compared to placebo and to find the appropriate dose for P3 study.
Detailed Description
To determine optimum dose of ASP0456 for the patients with chronic constipation (not including constipation due to organic diseases) in Japan based on its efficacy and safety, multicentered, placebo-controlled, double-blind, parallel group comparative study will be conducted.
After two-week observation period, the patient who meets the primary registration criteria will be randomized to the one from five groups and will start treatment period. The patients will take once daily orally before the breakfast for two weeks.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 20 Years to 79 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patient who had SBM* (Spontaneous bowel movement) less than 3 times per week, more than six months prior to the provisional registration
- •*Defecation without procedure of laxative, suppository, enema, or stool extraction on the day or preceding day of the defecation
- •Patient who was affected with one or more following symptoms before more than six months of provisional registration:
- •Straining during at least 25% of defecations
- •Lumpy or hard stools in at least 25% of defecations
- •Sensation of incomplete evacuation for at least 25% of defecations
- •Loose stools are rarely present without the use of laxatives more than six months prior to the provisional registration.
- •Patients who had pancolonoscopy or contrast enema (or sigmoidoscopy) after the onset of chronic constipation symptom and had no organic changes
Exclusion Criteria
- •Patient who has met IBS-C diagnostic criteria from Rome III more than six months prior to provisional registration. Meaning that patient who had recurrent abdominal pain or discomfort at least 3 days/month in last 3 months associated with two or more of the following, and patient who was affected with following IBS symptoms more than six months prior to the provisional registration:
- •Improvement with defecation
- •Onset associated with a change in frequency of stool
- •Onset associated with a change in form (appearance) of stool
- •Patient with history of surgical resection of stomach, gallbladder, small intestine, or large intestine (excluding resection of appendicitis and benign polyp)
- •Patient with history or current evidence of inflammatory bowel disease (Crohn's disease or ulcerative colitis)
- •Patient with history or current evidence of ischemic colitis
- •Patient currently affected by infectious enteritis
- •Patient currently affected by hyperthyroidism or hypothyroidism
- •Patient with apparent mechanical obstruction (i.e. patient with ileus caused by hernia)
- •Patient with mega colon or mega rectum
- •Patient currently affected by constipation due to anorectal dysfunction
- •Patient currently affected by drug induced constipation.
- •Patient with constipation due to other organic disease
- •Patient currently affected by active peptic ulcer
- •In the case of a female, the one currently affected by endometriosis or uterine adenomyosis
- •Patient with high depression or anxiety considered to influence drug evaluation
- •Patient with history of abuse of drug or alcohol within a year before consent acquisition, or with current abuse
- •Patient who used or underwent or will use or undergo drug/therapy/test prohibited to combine 3 days before the start of bowel habit observation period (Day -17) or thereafter (however, patient who used or underwent restricted drug/therapy according to Protocol may be enrolled provisionally)
- •Patient with history or current evidence of malignant tumor
- •Patient currently affected by serious cardiovascular disease, respiratory disease, kidney disease, hepatic disease, gastrointestinal disease (excluding CC), hemorrhagic disease, or neural/mental disease
- •Patient with history of drug allergy
Arms & Interventions
ASP0456 0.0625mg
Experimental
oral
Intervention: ASP0456 (Drug)
ASP0456 0.125mg
Experimental
oral
Intervention: ASP0456 (Drug)
ASP0456 0.25mg
Experimental
oral
Intervention: ASP0456 (Drug)
ASP0456 0.5mg
Experimental
oral
Intervention: ASP0456 (Drug)
Placebo group
Placebo Comparator
oral
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Change in weekly average of SBM frequency
Time Frame: From baseline to week 1
SBM: Spontaneous Bowel Movement. SBM means the defecation without procedure of laxative, suppository, enema, or stool extraction on the day or preceding day of the defecation. SBM frequency is calculated as follows: (the week total number of SBM )/ (the total number of days on which the frequency of SBM is evaluable) x7
Secondary Outcomes
- Weekly responder rate for CSBM(up to 2 weeks)
- Weekly responder rate of the abdominal bowel habits improvement in chronic constipation.(up to 2 weeks)
- Weekly responder rate of abdominal symptom relief of chronic constipation.(up to 2 weeks)
- Score of the global assessment of relief of chronic constipation(up to 2 weeks)
- Proportion of subjects with CSBM within 24 hours after the start of initial treatment(up to 24 hours)
- Percentage of subjects with SBM within 24 hours after the start of initial treatment(up to 24 hours)
- Changes in weekly average of stool form(From baseline to every week until 2 weeks)
- Changes in weekly average of straining severity scores(From baseline to every week until 2 weeks)
- Weekly responder rate of the global assessment of relief of chronic constipation.(up to 2 weeks)
- Changes in IBS-QOL-J scores (entire scores or scores on the sub-scales)(Week 0, and 2)
- Safety assessed by development of incidence of adverse events, vital signs, clinical laboratory tests and body weight(up to 2 weeks)
- Weekly responder rate for SBM(up to 2 weeks)
- Changes in weekly average of abdominal bloating severity scores(From baseline to every week until 2 weeks)
- Change in weekly average of CSBM frequency(From baseline to week 1)
- Score of the abdominal symptom relief of chronic constipation(up to 2 weeks)
- Changes in weekly average of SBM frequency(From baseline to every week until 2 weeks)
- Changes in weekly average of CSBM frequency(From baseline to every week until 2 weeks)
- Score of the abdominal bowel habits improvement in chronic constipation(up to 2 weeks)
- Changes in weekly average of abdominal pain/discomfort severity scores(From baseline to every week until 2 weeks)
Investigators
Study Sites (50)
Loading locations...
Similar Trials
Completed
Phase 2
A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel SyndromeConstipation-predominant Irritable Bowel Syndrome (IBS-C)NCT01714843Astellas Pharma Inc559
Completed
Phase 3
A Study of Oral Dosing of ASP0456 in Patients With Chronic ConstipationChronic ConstipationNCT02809105Astellas Pharma Inc186
Completed
Phase 3
Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel SyndromeIrritable Bowel Syndrome With Constipation (IBS-C)NCT02316899Astellas Pharma Inc500
Completed
Phase 2
A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on MethotrexateRheumatoid Arthritis (RA)NCT03257852Astellas Pharma Inc66
Completed
Phase 2
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe PsoriasisPsoriasisNCT01096862Astellas Pharma Inc124